Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program (SPIN-CHAT)
Scleroderma, Scleroderma, Systemic, Systemic Sclerosis
About this trial
This is an interventional supportive care trial for Scleroderma focused on measuring Scleroderma, Systemic Sclerosis, COVID-19, E-health, Anxiety, Mental health, Trial, Coronavirus, RCT
Eligibility Criteria
Inclusion Criteria:
- Classified as having SSc by a physician
- PROMIS Anxiety 4a v1.0 T-score greater than or equal to 55
- Have regular, reliable internet access
- Be fluent in English or French
Exclusion Criteria:
- Receiving counseling or therapy currently
- Having a positive test for the COVID-19 virus
Sites / Locations
- Sir Mortimer B. Davis Jewish General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
SPIN-CHAT: Videoconference Intervention
Wait-list Control
Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.